术后用万赛维效果怎么样

How is the effect after surgery?

The clinical trial conducted a double-blind, placebo-controlled trial on 326 high-risk patients with CMV susceptibility (D+/R-) after kidney transplantation to evaluate the efficacy and safety of Vancevir (valganciclovir hydrochloride tablets) in preventing CMV from 100 days to 200 days after transplantation.

Patients were randomly divided into 1:1 groups. One group received Vancevir (valganciclovir hydrochloride tablets) from 10 days to 200 days after transplantation, and the other group received Vancevir (valganciclovir hydrochloride tablets) from 10 days to 100 days after transplantation, followed by placebo treatment for 100 days.

CMV infection as judged by the Research Efficacy Committee includes CMV syndrome and tissue-infiltrating infection. The incidence of CMV infection within 6 months after transplantation was 12.1% in the Vancevir (valganciclovir hydrochloride tablets) group and 15.2% in the oral ganciclovir group. Most of the CMV infection cases that occurred after stopping preventive treatment (after 100 days) in the Vancevir (valganciclovir hydrochloride tablets) group were later than those in the ganciclovir group.

Vancevir (valganciclovir hydrochloride tablets) is a special antiviral drug mainly used for primary immunodeficiency disease/cytomegalovirus (CMV) infection/cytomegalocytic inclusion disease/idiopathic thrombocytopenic purpura/immune thrombocytopenic purpura.

  According to clinical trial research results, it is known that the therapeutic effect of Valganciclovir Hydrochloride Tablets is very significant. The successful development of this drug is good news for many patients. However, patients cannot blindly take this drug for treatment. Before receiving treatment with Valganciclovir Hydrochloride Tablets, patients should go to the hospital for a detailed examination and strictly follow the doctor's diagnosis and treatment recommendations.

Severe leukopenia/neutropenia/anemia/thrombocytopenia/pancytopenia and bone marrow failure including aplastic anemia have been reported in studies with Valganciclovir Hydrochloride Tablets.

Use Valganciclovir Hydrochloride Tablets with caution in patients who already have cytopenias/patients receiving myelosuppressive drugs/irradiation.

In patients with severe leukopenia/neutropenia/anemia/thrombocytopenia, treatment with hematopoietic growth factors may be considered. Blood cell count differentials and platelet counts should be obtained frequently during treatment with Valganciclovir Hydrochloride Tablets, especially in patients with renal insufficiency and those with previous leukopenia caused by ganciclovir or other nucleoside analogues.

Recommended related hot articles: /newsDetail/74004.html